Form 4: Nektar Therapeutics Executive Sells Shares to Cover Tax Obligations

Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,300 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Summary

• On February 19, 2025, Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 10,300 shares of Nektar Therapeutics common stock.
• The sale was executed to cover required tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.01, with individual transactions ranging from $1.00 to $1.04.
• Following the transaction, Zalevsky directly owns 316,604 shares of Nektar Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't inherently reflect a positive or negative view of the company's prospects.

Industry Context

Executive stock sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The sale itself doesn't necessarily indicate a negative outlook on the company, but it's a transaction investors often monitor.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it's a small percentage of the total outstanding shares and is related to tax obligations.

Key Dates

Keywords

Nektar Therapeutics, Jonathan Zalevsky, Form 4, Insider Trading, Stock Sale, RSUs, Tax Withholding, NKTR